South Africa moves to eliminate HIV threat with Lenacapavir rollout
South Africa officially launched Lenacapavir, a twice-yearly injectable HIV prevention drug, marking a major step in its fight against HIV/AIDS. The rollout, led by President Cyril Ramaphosa and Health Minister Dr. Aaron Motsoaledi, prioritizes vulnerable groups like adolescent girls, pregnant women, and sex workers, with 37,920 doses initially distributed across 360 high-burden health facilities.
South Africa began rolling out Lenacapavir, a long-acting injectable HIV prevention drug, in Mpumalanga on June 1, 2026, with President Cyril Ramaphosa and Health Minister Dr. Aaron Motsoaledi overseeing the launch at Lilian Ngoyi Stadium in Secunda. The initiative fulfills a commitment Ramaphosa made during the 2026 State of the Nation Address, where he announced plans for a "massive rollout" of the drug, which has shown high effectiveness in preventing HIV transmission. Lenacapavir, administered twice yearly, offers an alternative to daily oral PrEP, addressing barriers like adherence and clinic visits. The first batch of 37,920 doses arrived in April 2026, with distribution prioritizing adolescent girls and young women (up to age 24), pregnant and breastfeeding mothers, female sex workers, men having sex with men, transgender individuals, and injecting drug users. The government plans to start with 360 health facilities in high-burden districts. South Africa’s HIV response has seen progress since its 2010 campaign, with life expectancy rising to 66.9 years by 2025 (up from 54 in 2010) and maternal mortality dropping to 89 deaths per 100,000 live births by 2020 (down from 240 in 2010). Despite 8.15 million people living with HIV (12.9% of the population), the country has reduced HIV-related deaths through expanded treatment access, according to Statistics South Africa’s 2025 estimates. The South African National AIDS Council (SANAC) called the launch a ‘new chapter in HIV prevention,’ emphasizing collaboration between the government, civil society, and private sector. Health officials described Lenacapavir as a preventive medicine—not a vaccine—highlighting its potential to improve adherence and discretion for users who struggle with daily oral medications. The rollout coincides with the anniversary of Nkosi Johnson’s death in 2001, a prominent HIV/AIDS activist who died at age 12. The launch underscores South Africa’s commitment to ending HIV as a public health threat, building on its history as the site of the world’s largest HIV counseling, testing, and treatment program.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.